CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – August 25, 2026 – Nava Therapeutics is embarking on a Series B financing round as the biotechnology firm pursues human clinical testing of its delivery platform of genetic medicines.
Need help?
Contact usCAMBRIDGE, Mass. & PHILADELPHIA, Pa. – August 25, 2026 – Nava Therapeutics is embarking on a Series B financing round as the biotechnology firm pursues human clinical testing of its delivery platform of genetic medicines.